Abstract In order to evaluate the outcome of patients with breast cancer according to response after primary therapy and according to clinical and biologic baseline features, we identified patients who were treated with preoperative therapy and who underwent surgery at the European Institute of Oncology (IEO), Milan, Italy, between 1995 and 2006. The outcome of patients who achieved pathological complete remission (pCR) and patients with residual disease (RD) at final surgery was analyzed. Of the 687 patients treated with preoperative therapy, we identified 82 patients who achieved pCR (12%) and 605 patients with RD (88%). A statistically significant difference in disease-free survival (DFS), distant diseasefree survival (DDFS), and overall survival (OS) was observed for patients with pCR compared with those who had RD (5 year DFS 73% vs. 59% P = 0.029; 5 year DDFS 81% vs. 72% P = 0.085; 5 year OS 88% vs. 77% P = 0.033). At the multivariate analysis, for patients achieving pCR, large tumor size ([5 cm) correlated with worse DFS (HR 3.18; 95% CI 1.34-7.51); clinical nodal involvement was associated with poorer DFS and DDFS (HR 6.94; respectively). pCR after preoperative systemic therapy correlated with significant improved outcome. A substantial rate of relapse was observed for patients with large tumors and with clinical nodal involvement at baseline. Further improvement in adjuvant treatment might be warranted.
Introduction
Preoperative chemotherapy might be advantageous to acquire early information on disease response. In fact, the response to the primary treatment may be used as a prognostic marker, since it has been demonstrated to be associated with a longer disease-free survival (DFS) compared with no-response [1] [2] [3] [4] [5] [6] . In particular, the degree of response [pathological complete remission (pCR)] predicts overall outcome in terms of DFS [4] . Several large randomized studies have shown that patients achieving a pCR to chemotherapy have far better long-term survival than those who fail to respond to primary chemotherapy (incomplete responders) [7, 8] . In particular, excellent overall survival (OS) was observed in a recent report for patients who achieved pCR, irrespective of endocrine responsiveness and HER2 expression [7] . However, a large variation in the outcome of patients achieving a pCR was reported in the past, possibly related to different definitions of pCR and features of patients included.
Furthermore, not all patients who achieve a pCR remain free of recurrence, and the identification of patients at high risk of relapse, among those who achieve a pCR, remains the most difficult task. Indeed, the selection of factors predictive of responsiveness and related outcome to specific neoadjuvant and adjuvant treatment programs continues to represent a major research issue. Intrinsically different subtypes of breast cancer have been identified in the past years based on gene expression profiles and immunohistochemical (IHC) localization of selected targets, which might influence the responsiveness to preoperative therapies and the outcome after surgery [9] [10] [11] [12] .
The aim of this retrospective study is to evaluate, in a large series of patients who were homogeneously diagnosed and treated in a single institution, the outcome of patients who achieved pCR or presented residual disease (RD) at final surgery, according to the clinical and biologic baseline features. We conduct the analyses according to REMARK recommendations [13] .
Materials and methods

Patients
For this study, we considered eligible breast cancer patients who underwent radical surgery at the European Institute of Oncology (IEO) after primary chemotherapy.
Other eligibility criteria for the study included no previous chemotherapy/hormone therapy, performance status 0-2 (ECOG scale), and measurable lesions.
Patients were treated under best known multidisciplinary management. All the patients received preoperative chemotherapy (plus/minus endocrine therapy) and adequate local treatment.
Patients were treated with preoperative chemotherapy given during 3-week courses. Patients with partial remission or complete remission were selected as candidates to receive a maximum of eight courses. The regimens used during the conduct of the study included anthracyclinecontaining, taxane-containing, and navelbine-containing regimens, as previously reported [14] .
Postoperative local-regional irradiation (RT) was proposed to all those patients who underwent conservative surgery and to those patients with cT4 disease, and whenever indicated.
The selection of adjuvant systemic treatment was based on indicators of responsiveness to treatment (endocrine responsiveness of the tumor) and evaluation of risk. For patients with endocrine-responsive disease, adjuvant endocrine therapy alone, according to menopausal status was prescribed (tamoxifen or aromatase inhibitor) for a duration of 5 years in postmenopausal patients, while the combination of tamoxifen for 5 years plus gonadotropin-releasing hormone analogs for at least 2 years in premenopausal patients [15] . For patients who achieved pCR with non-endocrine-responsive disease, adjuvant metronomic chemotherapy for 4-6 months was proposed.
Specimen characteristics and assay methods
This is a single institution study. All the patients had pathological evaluation performed at diagnostic core biopsy and at final surgery at the IEO.
Surgical specimens were extensively sampled for the evaluation of residual tumor after primary chemotherapy. In cases of lack of gross evidence of tumor, the quadrantectomy specimens were entirely embedded in paraffin blocks and examined histologically, as were the tumorbearing quadrants of the mastectomies. In the latter cases, the other quadrants were also thoroughly evaluated with the examination of at least three tissue blocks.
Pathological complete remissions (pCRs) were evaluated according to the criteria proposed by Kuerer et al. [4] . In particular, the absence of invasive cancer on both the primary breast tumor and axillary lymph nodes qualified for pCR.
Immunostaining experiments for the localization of ER and PgR, HER2 protein, and Ki-67 antigen were performed on consecutive tissue sections from the tumor-containing blocks, as previously reported [14] . The immunostained slides were re-evaluated independently by two of the pathologists. The following primary antibodies were used: the monoclonal antibody (MAb) to ER (clone 1D5; Dako, Glostrup, Denmark at 1/100 dilution), the Mab to PgR (clone 1A6, Dako, at 1/800 dilution), the MIB-1 Mab to the Ki-67 antigen (Immunotech, Marseille, France, 1/1200), and the polyclonal antibody (Dako, 1/3200) to the HER2 protein.
Only nuclear reactivity was taken into account for ER, PgR, and Ki-67 antigen, whereas only an intense and complete membrane staining in [10% of the tumor cells qualified for HER2 overexpression (3?). The results for ER, PgR, and Ki-67 were recorded as the percentage of immunoreactive cells over up to 2,000 neoplastic cells. The value of 20% for Ki-67 labeling index (LI) was used as a cut-off in distinguishing tumors with low (\20%) and high ([20%) proliferative fraction [14] . Steroid hormone receptors status was classified as negative (lack of any ER and PgR immunoreactivity, or\1% immunoreactive tumor cells), incompletely endocrine responsive (ER and/or PgR \ 50% of the cells) or highly endocrine responsive (ER and PgR [ 50% of the cells).
Study design
We collected information through the institutional clinical database on all consecutive breast cancer patients treated at the IEO, Milan, Italy, between 1995 and 2006.
Data on the patient's medical history, concurrent diseases, type of surgery, histopathological features, and results of staging procedures (blood chemistry, hematologic values, bone scan, chest film, and upper abdominal ultrasound examination) were reviewed. We subsequently identified those patients treated with preoperative chemotherapy plus or minus concurrent endocrine therapy, and we selected patients who achieved pCR and patients with RD at final surgery.
Main endpoints were DFS, DDFS, and OS. DFS was defined as the length of time from the date of surgery to any relapse (including ipsilateral breast recurrence), the appearance of a second primary cancer (including contralateral breast cancer), or death. DDFS was defined as the length of time from the date of surgery to events such as distant recurrence, death from breast cancer, death from causes other than breast cancer (including unknown causes), or the development of a secondary primary invasive cancer. Data were censored on the date of the previous follow-up visit.
Statistical analysis methods
Pearson v
2 test was used to compare the pCR rates among levels of the considered variables.
Plots of the survival curves were drawn using the Kaplan-Meier method. The log-rank test was used to assess the survival difference between groups.
Cox's proportional hazard regression models were used to assess the prognostic significance of clinical and histopathological characteristics of the tumor on the evaluated outcomes. Factors that were significant at a P-value of 0.05 or less at the univariate analysis were entered into the multiple regression models. Results from Cox's models were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). All analyses were performed with the SAS software version 8.02 (SAS, Cary, NC, USA). All P-values were two sided.
Results
Data
One thousand five hundred forty-seven patients, who received primary therapy for breast cancer and submitted at surgery, were identified. Patients who presented with biopsy done elsewhere (n = 673), metastatic disease at presentation (n = 133), other previous tumor (n = 16), bilateral tumors (n = 36), and male breast cancers (n = 2) were excluded, leaving a total of 687 patients evaluable for this analysis.
Eighty-two (12%) patients who achieved pCR, and 605 (88%) patients with RD at final surgery were identified ( Fig. 1) . Table 1 shows the characteristics of the patients evaluated at diagnosis and their association with pCR probability. Those showing a statistically significant association were grade, extent of ER and PgR immunoreactivity, and Ki-67 labeling index.
Patients who achieved pCR more frequently presented non-endocrine-responsive disease, with triple negative breast cancer phenotype, high nuclear grade. 31% of patients who achieved pCR presented at baseline triple negative breast cancer phenotype with Ki-67 expression more than 20% of cells (Table 2) .
We reported, in overall population, an increased use of anthracycline and taxane combination in the later years of diagnosis compared to earlier; 56% of patients who were operated in the 2004-2006 received anthracycline and taxane combination compared to 15% of patients operated in the 1995-1999.
The anthracycline and taxane combination was more frequently associated with achievement of pCR as reported in Table 3 . Analysis and presentation
Median follow up was 60.9 months (range 5-152 months). The Kaplan-Meier curves for DFS and DDFS, according to type of response (pCR and RD) are displayed in Fig. 2 . The 5-year DFS and DDFS were 73 and 81% in the pCR group compared to 59 and 72% in the RD group (P = 0.029 for DFS and P = 0.085 for DDFS). Figure 3 shows the Kaplan-Meier curve for OS. Better OS was observed for patients who achieved pCR as compared to that of patients with RD, 5-year OS were 88 and 77% in the two groups, respectively (P = 0.033).
We investigated the prognostic significance of selected subgroups of patients with pCR and patients with RD. We identified three immunohistochemically defined tumor subtypes: triple negative (ER, PgR, and HER2 negative), HER2-positive and non-endocrine-responsive disease (HER2 positive, ER, and PgR negative) and endocrineresponsive (ER and or PgR [ 1% any status of HER2).
Figures 4 and 5 show the Kaplan-Meier curves for outcomes among the three subgroups of patients in patients with pCR and RD. DFS and DDFS were poorer for patients with HER2-positive disease, compared to those with triple negative and endocrine-responsive diseases for patients with pCR and for patients with RD. Significantly, worse OS was observed for patients with HER2-positive breast cancer compared to other patients in both the pCR group (P = 0.021) and RD group (P B 0.0001).
At the univariate analysis, clinical size of tumor greater than 5 cm was significantly associated with poorer DFS (HR 2.95; 95% CI 1.25-6.98), DDFS (HR 3.19; 95% CI 1.07-9.52) in patients that achieved a pCR. Also clinical lymph node involvement was significantly associated with increased risk of recurrence (HR 4.87; 95% CI 1.45-16.4 and HR 4.9; 95% CI 1.11-21.72 for DFS and DDFS respectively) in patients that achieved pCR.
Multivariate analysis
The independent association between biologic variables and the risk of recurrence in the pCR group and in the RD group was analyzed. The results, obtained using Cox proportional hazards regression analysis, are displayed in Tables 4a-b Clinical nodal involvement was found to be associated with a higher risk of worse DFS and DDFS (HR 6.94; 95% CI 1.62-29.73 and HR 9.87 95% CI 1.29-75.53 respectively).
Discussion
Several large randomized studies have shown that patients achieving a pCR to primary chemotherapy have far better long-term survival than those who fail to respond to primary chemotherapy (incomplete responders) [1] [2] [3] [4] . It has, therefore, been assumed that pCR is a valid surrogate marker of long-term survival and cure in patients with locally advanced breast cancer treated with preoperative chemotherapy even though the definition of pCR between studies was heterogeneous in the past studies [1] . Only recently, a more homogeneous definition of pCR (i.e., the absence of invasive carcinoma in either breast and axilla) has been accepted as a surrogate marker of better survival.
Several major conclusions can be drawn from this study. Although pCR might identify patients with significantly improved outcome, a substantial risk of relapse still persists for these patients. As previously shown, we reported significantly better outcome in terms of DFS, DDFS, and OS after primary chemotherapy for patients who achieved pCR compared to those with RD at final surgery. However, the 5-year DFS for patients with a pCR at final surgery was 73%, thus indicating that a non-negligible proportion of patients might experience an event despite the achievement of pCR. These results are consistent with those of previous studies that have reported recurrence rates in the range of 13-25% [1, 4, 16, 17] .
The finding that patients achieving a pCR remain at substantial risk of relapse was observed in a population subjected to an adjuvant therapy program which might have interfered with the outcome. It is noteworthy that in the present analysis medical oncologists used consistent approaches during the years of reference. The adjuvant treatment proposed was largely based on the degree of nodal involvement, as well as on known prognostic features according to the recent St. Gallen Consensus Conference Guidelines [15] . Consequently, the identification of ''niches'' of patients at major risk is key for future studies and further tailored adjuvant programs should be developed within these subgroups of patients.
In this study, we showed that the tumor diameter and the nodal clinical status at baseline are clinical features that might identify those patients at higher risk. Other groups showed that a more advanced disease (e.g., clinical stage IIIB/C and cT4d) at baseline might correlate with a worse outcome in patients who achieved pCR when compared with those patients with less advanced disease [18, 19] .
However, in this study, we found an independent prognostic role for both the tumor diameter and clinical nodal status. In particular, the tumor measurement might be of clinical value, since easily available and not subject to possible false positive results as opposed to the clinical nodal status.
We hypothesize that large tumor size and clinical nodal involvement at baseline could reflect a higher risk of systemic micrometastatic disease at diagnosis. Theoretically, the ability to achieve a pCR, might indicate high tumor chemosensitivity and therefore eradication of all distant invasive micrometastatic disease, with resulting low recurrence rates.
It might be argued, however, that with a more advanced disease stage there is a higher probability of micrometastatic clones, a subgroup of which may be resistant to conventional agents, or have different tumor features as compared with the primary tumors. This hypothesis might support further studies using additional agents in the adjuvant setting with a mechanism of action different from those used in the preoperative setting.
It should be emphasized that the subgroups at higher risk identified in the analysis of this study include a heterogeneous groups of tumors, and that the identification of specific niches of patients amenable to targeted treatments represents a research priority. In particular, in this study, we explored the role of HER2 overexpression, steroid hormone receptors, and the definition of subgroups (namely luminal, triple negative, HER2 positive) as recently reported [12] , but we were not able to identify subgroups with a different outcome after surgery. Possible reasons for these results include the low number of patients included in the analysis and the low number of events registered in studies focusing on a population that achieved a pCR.
In conclusion, we demonstrate that the achievement of a pCR after preoperative systemic therapy is correlated with significant improved outcome, although a non-negligible risk of relapse remains, in particular with patients with clinical large tumor size and clinical nodal involvement at baseline.
The results of this study provide substantial additional evidence to support the concept that further progress in the adjuvant treatment of breast cancer will require studies dedicated to specific ''niches'' of patients identified through both clinical and biologic features.
